Tag Archives: Slow

Chicago Short Sales Nevertheless on the Rise Slow Housing Industry Recovery Predicted

Posted on by


Chicago, IL (PRWEB) June 07, 2011

Down 19.two % from April of last years, the number of current home sales in April 2011 in the Chicago area showed an increase of 7.3 % from that of March as the traditionally busier spring property-purchasing season set in. A considerable percentage of these home sales had been quick sales, according to Chicago and Westchester brief sale specialists Denise and James Orrico.

&#13

Identified as the Orrico Team, they are closely monitoring trends in the real estate marketplace in the region, 1 of the most substantial of which is the rise in quick sales. Citing U.S. Treasury Secretary Timothy Geithners not too long ago released statement on housing recovery, they also report that the marketplace is most likely going to take a few a lot more years to recover.

&#13

We dont see the housing marketplace making a full recovery yet this year or, certainly, if house sales and rates will ever go back to the levels that they have been at just before the recession, says Denise Orrico. Nevertheless, there is some relief for underwater property owners in the reality that the banks are selecting up their speed a bit when it comes to negotiations for both brief sales and REO or foreclosure properties.

&#13

There has been a rise in Chicago brief sales considering that the start of the downturn and its a quantity that could boost if the bill being considered in Congress must pass, adds James Orrico. He is referring to H.R.1498, the Prompt Decision for Qualification of Brief Sale Act of 2011, which provides lenders a 45-day deadline for deciding on short sale provides. If passed, the bill could aid shorten and simplify the quick sale process.

&#13

For several distressed home owners in danger of losing their home to foreclosure, a quick sale is frequently the very best selection. The Orrico Group has substantial knowledge with short sales throughout the Chicago metro location, like Glen Ellyn short sales for sale. The group performs mainly with home owners who are underwater with their mortgages and have been unable to have a loan modification approved.

&#13

Possibly theyve lately been by way of a divorce or have had their incomes lowered due to job loss or a death in the household, or possibly they need to move but cannot sell their home for the quantity that they owe on their mortgagewe realize how unpredictable life can be and our goal is to assist our customers uncover the ideal answer, says Denise. If they are considering about receiving the short sale method started, Jim and I are here to help with all facets of a brief sale, from listing to promoting to coaching and counseling. The Orrico Team closes on 99% of the listings that they obtain contracts on and this is quite an impressive success price thinking about the complexity of brief sale negotiations.

&#13

To learn more about the Orrico Teams quick sale solutions and the actual estate industry in Chicago, visit their internet site at http://www.OrricoTeam.com or get in touch with them straight.

&#13

###

&#13
&#13
&#13
&#13
&#13

Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld

Posted on by


Los Angeles, CA (PRWEB) May 25, 2013

IBISWorld estimates that revenue for the Cell Therapy industry will grow at an average annual rate of 28.7% to $ 1.0 billion in the five years to 2013, including growth of 17.9% in 2013. From 2002 and 2008, no new cell therapy products were introduced, according to IBISWorld industry analyst Kevin Culbert, causing relatively modest growth during that period. In the years since, however, the Food and Drug Administration (FDA) has approved six new products. This factor contributed to the industry’s fast growth during the five years to 2013.

In 2011, the release of Dendreon’s Provenge contributed to revenue growth of 59.5% during the year. The product got a significant boost when Medicare announced that it would cover the cost of reimbursement. In spite of this, the treatment’s reception was expected to be considerably greater. Slow adoption was partially caused by the treatment’s high sticker price (due to its high cost of development), a factor that has led many doctors to use alternative treatments, Culbert says. Industry operators have spent billions of dollars trying to develop a blockbuster treatment that will yield billions of dollars in return. Wage costs contribute significantly to the Cell Therapy industry s high operational costs. In 2013, for example, wages alone are expected to represent 118.5% of industry revenue, causing the industry to operate at a loss throughout its existence.

During that time, industry operators will benefit from the research and development (R&D) that has taken place over the past five years and the clinical trials that are currently in place. The industry will also benefit from the FDA’s Safety and Innovation Act, which was signed into law in July 2012. The act will accelerate the approval process for drug manufacturers, including regenerative medicine products. In spite of this factor, industry firms are expected to continue operating at a loss over the next five years as vast sums of money are poured into R&D. In addition to Dendreon, current major players include Shire Pharmaceuticals, Organogenesis Inc. and NuVasive Inc.

The Cell Therapy industry has a high level of market share concentration. Given that the industry is in the growth stage of its life cycle and it typically takes a number of years to bring a product to market, there is a large number of smaller companies in the industry that are still in the product development stage and awaiting FDA approval. There are currently only about 40 cell therapy products available on the commercial market, according to the Alliance for Regenerative Medicine’s annual report. Consequently, market share concentration is expected to decrease over the next five years as new products are introduced to the commercial market. For more information, visit IBISWorlds Cell Therapy in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry engineers human tissue, also known as cell therapy or regenerative medicine. Tissue engineering is the use of a combination of cells, engineering and materials methods, and suitable biochemical and chemical factors to improve or replace biological functions. Key functions include repairing or replacing tissues (e.g. bone, cartilage, blood vessels and skin).

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nations most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Find More Administrator Press Releases